Denali Therapeutics, Inc. (DNLI)
22.59
-0.26
(-1.14%)
USD |
NASDAQ |
Sep 03, 10:01
Denali Therapeutics Research and Development Expense (TTM) : 400.72M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 400.72M |
| March 31, 2026 | 406.40M |
| December 31, 2025 | 418.78M |
| September 30, 2025 | 420.66M |
| June 30, 2025 | 416.95M |
| March 31, 2025 | 405.65M |
| December 31, 2024 | 396.44M |
| September 30, 2024 | 404.46M |
| June 30, 2024 | 395.96M |
| March 31, 2024 | 402.08M |
| December 31, 2023 | 423.88M |
| September 30, 2023 | 408.18M |
| June 30, 2023 | 406.23M |
| March 31, 2023 | 401.45M |
| December 31, 2022 | 358.73M |
| September 30, 2022 | 334.50M |
| June 30, 2022 | 318.27M |
| March 31, 2022 | 291.24M |
| December 31, 2021 | 265.35M |
| Date | Value |
|---|---|
| September 30, 2021 | 252.22M |
| June 30, 2021 | 234.36M |
| March 31, 2021 | 221.81M |
| December 31, 2020 | 212.62M |
| September 30, 2020 | 209.42M |
| June 30, 2020 | 208.26M |
| March 31, 2020 | 205.20M |
| December 31, 2019 | 191.58M |
| September 30, 2019 | 179.94M |
| June 30, 2019 | 157.72M |
| March 31, 2019 | 151.87M |
| December 31, 2018 | 135.28M |
| September 30, 2018 | 113.04M |
| June 30, 2018 | 100.45M |
| March 31, 2018 | 75.22M |
| December 31, 2017 | 72.88M |
| September 30, 2017 | 71.26M |
| June 30, 2017 | 80.94M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 699.56M |
| Oncolytics Biotech, Inc. | 13.11M |
| Sangamo Therapeutics, Inc. | 113.79M |
| Sarepta Therapeutics, Inc. | 783.60M |
| Anixa Biosciences, Inc. | 4.557M |